EMAX CASE STUDIES
PRE-EMPTING REIMBURSEMENT BARRIERS FOR A RARE DISEASE THERAPY ACROSS 6 ASIAN MARKETS
Identify likely pushback from pricing and reimbursement authorities to two new rare disease therapies in Australia, China, Japan, Korea, Singapore and Taiwan.
Given the different nature of the P&R systems of the markets in scope, as well as the different launch status of the products in question, we used different approaches across the markets in-scope to generate insights to help our client make decisions on pricing and reimbursement strategy.
For Australia and Taiwan, we ran a mock payer negotiation exercise in Singapore, with the client’s country teams ‘pitching’ their case for reimbursement to a panel of ex-payers and handling their objections.
For Japan, we ran advisory board-style meetings with academic advisors to the government to help advise on how to make the best case for a price premium.
For China, Korea and Singapore we conducted interviews (some F2F, some by telephone) with payers, payer advisors and hospital social workers to test value messages and identify the best route to funding.
By soliciting insights from senior payers and ex-payers we were able to provide the client with a set of actionable insights and recommendations for how to make the strongest case possible for favourable pricing and reimbursement, specific to each market.